THC and CBD generally gain all the glory but breeders are now developing strains rich in other cannabinoids
Producers are constantly selecting new varieties of cannabis and some of them are trying to create strains with high concentrations of unusual cannabinoids. More specifically, the breeders community is about to market cannabis varieties rich in tetrahydrocannabivarin (THC-V), cannabidivarin (CBD-V) and cannabigerol (CBG).
These new varieties with high levels of THC-V, CBD-V and CBG are created by selection techniques combined with extensive laboratory testing. This means that mother plants with known levels of cannabinoids are crossed and the seeds are collected and grown. Normally, some of the offspring will show higher levels of the desired cannabinoid than the parents. These products are crossed and the process continues over several generations. It is a laborious and time consuming process, but it is the only way to create high levels of desired cannabinoids.
It is also the same process that was used several years ago to create the first varieties rich in CBD, those that contain 4% or more CBD in the dried heads. For the moment, we still do not know what will be the final level of THC-V and CBD-V in these new strains but it could be around 2 to 7%, with a maximum objective of 10%. Cannabigerol levels should be around 4% once stabilized.
Farmers are constantly selecting new varieties of cannabis, and some of them are trying to create strains with unusually high concentrations of cannabinoids. The breeders community is very close to bringing to market cannabis varieties rich in tetrahydrocannabivarin (THC-V), cannabidivarin (CBD-V), and cannabigerol (CBG). The first of these varieties was born in last may at the Polytechnic University of Valencia.
As the name suggests, THC-V has a molecular structure similar to that of THC with some slight differences. Tetrahydrocannabivarin is psychoactive, and early indications suggest that THC-V may have the potential to increase the euphoric effects of THC. So this could be a cannabinoid that is of great interest to recreational users. Of course, users for medical purposes could find a great use of THC-V. In fact, GW Pharmaceuticals invests heavily in THC-V research as a possible oral drug to treat diabetes.
Tetrahydrocannabivarin has a high boiling point, approximately 220 ° C. It may therefore be necessary for your vaporizer to be set at a higher temperature to release it. For comparison, THC boils at about 160 ° C.
Cannabidivarin is a non-psychoactive cannabinoid, which means that it will not make you climb very high and that its chemical structure is very similar to that of CBD. It has been found naturally at reasonably high levels in some indica varieties of northern India, near mountainous areas, as well as in some varieties of Nepal. Some of the highest concentrations of CBD-V are in the Nepali hash . The elders will remember the legendary Temple Balls, one of the most sought-after varieties of hashish in the past.
Today, the CBD-V is already receiving a lot of medical attention from GW Pharmaceuticals, which is impressed by its anticonvulsant properties. Long-Term Medical Research Focuses on Medications antiepileptic for adults and children. Again, many questions about the function and effect of this cannabinoid remain unanswered. However, given that large pharmaceutical companies are already investing heavily in CBD-V, it seems likely that medical evidence of CBD-V efficacy is building up.
Cannabigerol, considered non-psychoactive, is the nonacidic version of cannabigerolic acid (CBGA). Cannabigerolic acid is often referred to as the "mother cannabinoid", which is the starting point from which other cannabinoids are created.
In most cannabis varieties, much of the CBG is converted to other cannabinoids, usually THC or CBD. As a result, most cannabis strains have less than 1% CBG in the plant at the time of harvest. However, selective selection has increased CBG levels from 2 to 3% in research varieties, and this increase could be further increased before the release of the first variety of CBG. Ongoing research will confirm many of the medical benefits of CBG, but may have potential uses as a neuroprotective, pain, anxiety, anti-inflammatory and antiseptic.
An exciting time for cannabis
No one really knows all the medical benefits THCV, CBDV and CBG could offer. Although some research has been done on these new cannabinoids, little is known about how they will interact with other cannabinoids in high concentrations. For example, will the new cannabinoids amplify the effects of other cannabinoids or will they neutralize them? Will the new cannabinoids be the most appreciated by medical users or will they give recreational users new levels of satisfaction and pleasure? Only time will tell.
CBD-based varieties were just the first wave of new varieties rich in cannabinoids. Many were surprised at the impact of CBD-based varieties. It will be fascinating to see how the new varieties of cannabinoids will eventually be received.
an article proposed by Maximum Yield